Targeting and killing glioblastoma with monoclonal antibody to  O -acetyl GD2 ganglioside

Julien Fleurence; Denis Cochonneau; Sophie Fougeray; Lisa Oliver; Fanny Geraldo; Mickaël Terme; Mylène Dorvillius; Delphine Loussouarn; François Vallette; François Paris; Stéphane Birklé

doi:10.18632/oncotarget.9226

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside

Julien Fleurence, Denis Cochonneau, Sophie Fougeray, Lisa Oliver, Fanny Geraldo, Mickaël Terme, Mylène Dorvillius, Delphine Loussouarn, François Vallette, François Paris and Stéphane Birklé _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:41172-41185. https://doi.org/10.18632/oncotarget.9226

Metrics: PDF 2211 views | HTML 3311 views | ?

Abstract

Julien Fleurence1,2,*, Denis Cochonneau3,*, Sophie Fougeray1,2,4, Lisa Oliver1,2,5, Fanny Geraldo1,2, Mickaël Terme3, Mylène Dorvillius3, Delphine Loussouarn1,2,5, François Vallette1,2,6, François Paris1,2,5,6, Stéphane Birklé1,2,4

1INSERM U892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, France

2CNRS 6299, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, France

3OGD2 Pharma, Institut de Recherche en Santé de l’Université de Nantes, Nantes, France

4Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France

5Centre Hospitalier Universitaire de Nantes, Nantes, France

6LaBCT, Institut de Cancérologie de l’Ouest-René Gauducheau, Saint-Herblain, France

*These authors contributed equally to this work

Correspondence to:

Stéphane Birklé, email: [email protected]

Keywords: glioblastoma, ganglioside, immunotherapy

Received: September 29, 2015 Accepted: April 22, 2016 Published: May 09, 2016

ABSTRACT

There are still unmet medical needs in the treatment of glioblastoma, the most common and the most aggressive glioma of all brain tumors. Here, we found that O-acetyl GD2 is expressed in surgically resected human glioblastoma tissue. In addition, we demonstrated that 8B6 monoclonal antibody specific for O-acetylat GD2 could effectively inhibit glioblastoma cell proliferation in vitro and in vivo. Taken together, these results indicate that O-acetylated GD2 represents a novel antigen for immunotherapeutic-based treatment of high-grade gliomas.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9226

Publication Alerts

Research Papers:

Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside

Abstract